Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 2,840 matching trials from the live ClinicalTrials.gov search.
Conditions
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
ST101, Temozolomide, Radiation
Drug · Radiation
Lead sponsor
Sapience Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
Conditions
Renal Cancer, Melanoma
Interventions
Aldesleukin, Sorafenib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Metastatic Breast Cancer
Interventions
carboplatin, bevacizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Park Ridge, Illinois
Conditions
Advanced Solid Tumors
Interventions
AMG 650
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Santa Monica, California • Indianapolis, Indiana + 10 more
Conditions
Breast Neoplasm
Interventions
Tesetaxel once every 3 weeks, Tesetaxel once weekly
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
New York, New York • Greensboro, North Carolina • Memphis, Tennessee + 1 more
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
brentuximab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 57 more
Conditions
Cancer, Melanoma
Interventions
Radiation Therapy, Cisplatin, Surgical resection
Radiation · Drug · Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Salt Lake City, Utah
Conditions
Breast Cancer
Interventions
pyrazoloacridine
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
16 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
5
States / cities
Lexington, Kentucky • Columbus, Ohio • Greenville, South Carolina
Conditions
Progressive Metastatic Malignancies
Interventions
ALT-801
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more
Conditions
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Interventions
1.0% IP-001 for Injection
Drug
Lead sponsor
Immunophotonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma
Conditions
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
35
States / cities
San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more
Conditions
Metastatic ER+ Her2- Breast Cancer, Postmenopausal
Interventions
Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Fresno, California • Los Angeles, California + 21 more
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Comprehensive Outcomes for After Cancer Health

NCT05349227
Conditions
Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Interventions
Digital Health Coaching Program, Fitbit
Behavioral · Device
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more
Conditions
Breast Cancer
Interventions
Bevacizumab, Docetaxel, CPT-11, Paclitaxel, Vinorelbine Tartrate, Gemcitabine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina + 1 more
Conditions
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions
Radiotherapy, MEDI4736, Tremelimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
Biological · Procedure
Lead sponsor
Carlo Contreras
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases

NCT00592462
Conditions
Breast Cancer
Interventions
Whole Body MRI
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
LY573636-sodium
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Tampa, Florida • Indianapolis, Indiana • Portland, Oregon + 2 more
Conditions
HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Discontinuation of Anti-HER-2 Maintenance Treatment
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
Interventions
Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review
Procedure · Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
3
States / cities
San Francisco, California • The Bronx, New York • Durham, North Carolina
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Ipilimumab, Nivolumab, Cryoablation
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts